Novo Nordisk AS has posted a healthy set of financials for the second quarter, helped by the strong launch of the injectable Ozempic (semaglutide) but all eyes are now on the third quarter and the expected US approval of the closely watched oral version of the once-weekly GLP-1 type 2 diabetes drug.
Ozempic Q2 sales came in at DK2.33bn ($349m), topping analyst consensus by 26%, and on a conference call, CEO Lars...








